We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Volatile Anesthetics in Cardiac Protection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00364637
Recruitment Status : Recruiting
First Posted : August 15, 2006
Last Update Posted : February 28, 2018
Information provided by (Responsible Party):
Giovanni Landoni, Università Vita-Salute San Raffaele

August 11, 2006
August 15, 2006
February 28, 2018
January 2005
May 2020   (Final data collection date for primary outcome measure)
Reduce postprocedural cardiac troponin release
Same as current
Complete list of historical versions of study NCT00364637 on ClinicalTrials.gov Archive Site
  • Reduce time on mechanical ventilation, Intensive Care Unit (ICU) and hospital stay
  • mortality
Reduce time on mechanical ventilation, ICU and Hospital stay, mortality.
Not Provided
Not Provided
Volatile Anesthetics in Cardiac Protection
Pharmacological Preconditioning Properties of Volatile Anesthetics

Patients undergoing stenting procedures, or cardiac or non-cardiac surgery could develop myocardial damage as testified by cardiac troponin release.

Sevoflurane (volatile anesthetic), routinely used in cardiac and non-cardiac anesthesia, has cardioprotective properties that could be useful to reduce cardiac damage, as indicated by cardiac troponin release in different contexts:

  • stenting procedures (periprocedural administration)
  • non-cardiac surgery (during the whole procedure)
  • cardiac surgery (during the whole procedure)

Stenting procedures, cardiac and non-cardiac surgical procedures may carry a significant risk of cardiac damage ultimately leading to prolonged hospital stay and even a non-negligible periprocedural mortality rate. According to the American College of Cardiology/American Heart Association Guidelines all anesthetic techniques and drugs have known cardiac effects that should be considered in the perioperative plan. There appears to be no one best myocardium protective anesthetic technique: the choice of anesthesia is best left to the discretion of the anesthesia care team. To date no anesthesiological drug or techniques proved to reduce perioperative morbidity and mortality in cardiac surgery, only Beta-blockers and locoregional analgesia showed improved outcomes after non-cardiac surgery and no study on anesthesiological drugs has been performed in stenting procedures.

Volatile anesthetics, which are commonly used in general anesthesia to induce and maintain hypnosis, analgesia, amnesia and mild muscle relaxation, have been shown to improve post-ischemic recovery at the cellular level, in isolated hearts, and in animals, both through a pharmacological preconditioning and postconditioning action. Whether the cardioprotective effects of volatile anesthetics are clinically applicable and associated with improved cardiac function, ultimately resulting in a better outcome in patients undergoing cardiac surgery, is still debated. No data exist on patients undergoing non-cardiac surgery or stenting procedures.

A recently published meta-analysis including studies considering all volatile anesthetics showed no reduction in myocardial infarction and perioperative death rate. However the newer volatile anesthetics (desflurane and sevoflurane) seem to have more prominent cardioprotective properties and numerous apparently positive reports targeted to surrogate end-points, yet severely underpowered, have appeared in the literature. Of interest, many of these studies were not included in the above cited meta-analysis.

To address the question of whether the choice of an anesthetic regimen might influence patients' outcome we have planned a RCT to determine the impact of sevoflurane on perioperative cardiac damage in patients undergoing cardiac surgery, non-cardiac surgery and stenting procedures.

Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Prevention
  • Drug: Sevoflurane (Volatile Anesthetic)
  • Drug: Total intravenous anesthesia
  • Active Comparator: Total intravenous anesthesia
    Intervention: Drug: Total intravenous anesthesia
  • Experimental: sevoflurane
    Intervention: Drug: Sevoflurane (Volatile Anesthetic)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
June 2020
May 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Cardiac surgery
  • Non-cardiac surgery
  • Stenting procedures

Exclusion Criteria:

  • Age < 18 years old
  • Not signing written consent
Sexes Eligible for Study: All
18 Years to 100 Years   (Adult, Senior)
Contact: Giovanni Landoni, MD +39.347.2520801 landoni.giovanni@hsr.it
DS/URC/ER/mm 51/DG
Not Provided
Not Provided
Not Provided
Giovanni Landoni, Università Vita-Salute San Raffaele
Università Vita-Salute San Raffaele
Not Provided
Principal Investigator: Giovanni Landoni, MD Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia
Study Director: Alberto Zangrillo, MD Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia
Università Vita-Salute San Raffaele
February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP